B7A23896-4182-48D3-A1D9-92C781BF283F
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 17.641261498028907
- age_years
- 53
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.627
- INTERFERON_GAMMA_RESPONSE+0.603
- ALLOGRAFT_REJECTION+0.515
- TNFA_SIGNALING_VIA_NFKB+0.513
- IL6_JAK_STAT3_SIGNALING+0.512
- ANGIOGENESIS+0.502
- INFLAMMATORY_RESPONSE+0.481
- APOPTOSIS+0.476
- MTORC1_SIGNALING+0.468
- E2F_TARGETS+0.451
Top 10 suppressed
- KRAS_SIGNALING_DN-0.360
- SPERMATOGENESIS-0.298
- MYOGENESIS-0.195
- ESTROGEN_RESPONSE_EARLY-0.092
- WNT_BETA_CATENIN_SIGNALING-0.085
- HEDGEHOG_SIGNALING-0.075
- PANCREAS_BETA_CELLS-0.043
- ESTROGEN_RESPONSE_LATE-0.029
- HEME_METABOLISM-0.005
- APICAL_SURFACE+0.028
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 53B31ABD-AD68-4A44-A525-23FD413115D5 | — | — | 0.975 |
| 2 | 9BFF7746-9003-4941-9590-0B813E00B326 | — | — | 0.972 |
| 3 | 3027792F-79B6-4729-9452-C4A72A7C4686 | — | — | 0.970 |
| 4 | F9A39954-57EB-4A3F-97A0-1801B08BBD53 | — | — | 0.969 |
| 5 | 8B4E465B-0FD5-4154-824B-1E6B2656FD2F | — | — | 0.969 |
| 6 | 7876A884-F031-42AB-ADC0-89589760FB6B | — | — | 0.969 |
| 7 | SRR934897 | — | — | 0.968 |
| 8 | DF145DF3-D7FD-48C9-ADC8-0B8618DC65A8 | — | — | 0.968 |
| 9 | D8A3D7E7-BDC0-42FF-B451-E25F472E8612 | — | — | 0.967 |
| 10 | SRR934874 | — | — | 0.967 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.627 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.603 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.515 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.513 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.512 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.502 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.481 | Idelalisib | — uncovered |
| APOPTOSIS | 0.476 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.468 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.451 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.428 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.409 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.401 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.398 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.396 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.389 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.387 | Inavolisib | — uncovered |
| COMPLEMENT | 0.368 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.368 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.360 | Inavolisib | — uncovered |